Professor Fu’s field of expertise includes anticancer drug pharmacology, toxicology, molecular mechanism of anticancer drugs and individual cancer chemotherapy. In recent years, he mainly focused on the study of drug resistance of cancer cells (especially multidrug resistance), the innate resistance of cancer stem cells and the individual cance r chemo the rapy. Fo r the excellent wo rk in the research o f “Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells”, Prof. Fu’s team gained the first prize of “Chinese Anti-Cancer Association (CACA) Science and Technology Award” (Ranked first) and the second prize of “Institute of Higher Education Outstanding Scientific Research Achievements Award” (Natural Science Award) in 2011. Prof. Fu has presided over and successfully comple ted mo re than 40 key research projec ts on na tional, provincial and ministerial scale and horizontal fund projects. More than 200 research papers have beenpublishedhavebeenpublishedinhigh-qualitySCljournals.

Personalized chemotherapy.

Department of Pathology and Lab Medicine, Medical University of South Carolina.

Charleston, USA.

1993.9.-1996.7. Ph.D. Program of Medicine

Cancer Center, Sun Yat-Sen University of Medical Sciences (SUMS), (now rename to: Sun Yat-sen University), Guangzhou, 510060, P. R.China.

1990.9.-1993.7. M. S. Program of Medicine

Department of Toxicology, Sun Yat-Sen University of Medical Sciences (SUMS), (now

rename to: Sun Yat-sen University), Guangzhou, 510080 P. R. China.

1982.9.-1987.7. M.D.

Department of Medicine, Guangdong Medical and Pharmaceutical College (rename

to Guangdong pharmaceutical College since 1993), Guangzhou, 510024 P.R.China.

2.Yang K#, Fu K#, Zhang H, Wang X, To KKW, Yang C, Wang F, Chen ZS, Fu L*. PBA2, a novel inhibitor of the beta-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR- ABL T315I mutation.  Mol Cancer. 2024 Sep 28;23(1):209.

3. Luo M, Wang X, Wu S, Yang C, Su Q, Huang L, Fu K, An S, Xie F, To KKW, Wang F, Fu L*. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal. Signal Transduct Target Ther. 2023 Aug 23;8(1):312.

4. Rong QX#, Wang F#, Guo ZX, Hu Y, An SN, Luo M, Zhang H, Wu SC, Huang HQ*, Fu LW*. GM-  CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. Mol Cancer. 2021 May 29;20(1):80.

5. Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L*. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung  cancer. Mol Cancer. 2021 Jan 18;20(1):17.

6. Luo M, Wang F, Zhang H, To KKW, Wu S, Chen Z, Liang S, Fu L *. Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. Signal Transduct Target Ther. 2020 Aug 28;5(1):141.

7. Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bartrons R, Fu L*, Chen G*. p38γ MAPK is essential for aerobic glycolysis and pancreatic tumorigenesis. Cancer Res. 2020 Jun 24:3281.

8. Wang X, Qiao D, Chen L, Xu M, Chen S, Huang L, Wang F, Chen Z, Cai J, Fu L*. Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. Mol Cancer. 2019 Dec 12;18(1):182.